BIOCON Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > biocon

Technical Analysis

Technical Strength: 7.7 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 61.1. According to RSI analysis, biocon is strong. 7.0 BIOCON RSI Chart
MACD (?) MACD: 20.1 and Signal Line: 15.5. According to MACD analysis, biocon is technically strong. 8.0 BIOCON MACD Chart
Simple Moving Average (?) According to simple moving average analysis, biocon is in a strong uptrend. Major support levels are 958.845, 925.816, 809.0472. 10.0 BIOCON Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, biocon is in a strong uptrend. Major support levels are 966.8549, 941.7042, 819.2428. 10.0 BIOCON Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.825. According to bollinger bands, biocon is technically strong. 7.0 BIOCON Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 986.7909 and 966.725. Resistance level is 1051.75. 6.5 BIOCON Fibonacci Retracement Chart
Average True Range (?) ATR: 28.7 NA BIOCON Average True Range Chart
Average Directional Index (?) ADX is 19.7 which means BIOCON is in a trading range and there is no trend. NA BIOCON Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
January 16, 2017
Open Price 994.9
High Price 1012.0
Low Price 980.0
Close Price 997.95
Absolute Change 3.5
Percentage Change 0.352%
Weekly Change -1.54%
Monthly Change 3.18%
Yearly Change 92.6%
52-week high 1051.75
52-week low 431.0
Corporate Actions
ExDate Purpose
June 22, 2016 ANNUAL GENERAL MEETING
March 17, 2016 INT DIV-RS 5 PER SHARE
March 17, 2016 INTERIM DIVIDEND
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.753
Confidence in Beta5.42%
Market Capital Rs. 19956.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 43.67
TTM Price-to-Earnings (P/E) Ratio 22.9
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 16 January 2017: Deliverable Quantity:1.15e+05 NA BIOCON Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 16 January 2017: Daily Volatility:0.363 NA BIOCON Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 16 January 2017: PCR_OI:0.343 PCR:0.379 NA BIOCON PCR Chart
Premium (?) 16 January 2017 Premium: 3.45 Futures OI:2934600.0 NA BIOCON Premium Chart
Option_MAX_OI (?) 16 January 2017: Price:997.95 Put with maximum OI:980.0 Call with maximum OI:1040.0 NA BIOCON Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
January 25, 2017 1001.4 2934600.0 2997.0 3260.0 997.95
February 23, 2017 1005.35 485400.0 125.0 174.0 997.95
March 30, 2017 1008.1 3600.0 3.0 3.0 997.95

Option Chains - NSE

BIOCON Option Zone

Announcements

January 12, 2017 BiocPress Releasecon Limited has informed the Exchange regarding a press release dated January 11, 2017, titled "U.S. FDA Accepts Biologics License Application (BLA) for
December 27, 2016 BiocPress Releasecon Limited has informed the Exchange regarding a press release dated December 27, 2016, titled "Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon s Proposed Biosimilar Trastuzumab Phase 3 Data".
See all Announcements

Board Meetings

Date Meeting Date Purpose
December 27, 2016 January 24, 2017 InteResults/Otherser alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended December 31, 2016 amongst other routine matters.
October 07, 2016 October 20, 2016 inteResultser alia, to approve the un-audited financial results for the quarter and period ended on September 30, 2016.
See all Board Meetings

BIOCON is part of...

Index Weightage
CNXMIDCAP 0.6
CNX500 0.08

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 949.3 Rs. 964.6 Rs. 981.3 Rs. 996.6 Rs. 1013 Rs. 1029 Rs. 1045